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The lung is a particularly vulnerable organ at the interface of the body and the exterior
environment. It is constantly exposed to microbes and particles by inhalation. The innate
immune system needs to react promptly and adequately to potential dangers posed by
these microbes and particles, while at the same time avoiding extensive tissue damage.
Nucleotide-binding oligomerization domain-like receptors (NLRs) represent a group of key
sensors for microbes and damage in the lung. As such they are important players in various
infectious as well as acute and chronic sterile inflammatory diseases, such as pneumonia,
chronic obstructive pulmonary disease (COPD), acute lung injury/acute respiratory distress
syndrome, pneumoconiosis, and asthma. Activation of most known NLRs leads to the pro-
duction and release of pro-inflammatory cytokines, and/or to the induction of cell death.
We will review NLR functions in the lung during infection and sterile inflammation.
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INTRODUCTION
The respiratory tract constitutes a large surface of the body with the
outside environment that is exposed to high volume airflow and
large numbers of inhaled microbes and particles. The microflora of
the upper respiratory tract consists of non-pathogenic bacteria but
also frequently comprises potential pathogens such as Streptococ-
cus pneumoniae and Staphylococcus aureus (1). The distal bronchi
and the alveoli have long been considered sterile, however more
recently microbes that are either aspirated from the upper respira-
tory tract (2) or constantly reside in the lower airways (3, 4) have
been found by culture-independent approaches.
Inflammatory disorders of the respiratory tract involving the
innate immune system include both infectious and non-infectious
diseases. Lower respiratory tract infections, or pneumonia, gener-
ally develop when facultative pathogenic microbes that colonize
the upper respiratory tract are aspirated or airborne pathogens
are inhaled. The World Health Organization (WHO) estimates
429 million cases of acute lower respiratory tract infections in
2004, making it the third leading cause of death world-wide (5).
Moreover, non-infectious and chronic lung diseases substantially
contribute to morbidity. Chronic obstructive pulmonary disease
(COPD) is mainly caused by tobacco smoke and can exacerbate
during acute infections, ranks as the number four leading cause of
death in most industrialized countries (5). Acute lung injury (ALI)
and its severest form, called acute respiratory distress syndrome
(ARDS), can develop after infectious as well as non-infectious
insults (6). Another potentially life-threatening disorder is allergic
asthma, which is characterized by airway hyperresponsiveness due
to allergen-triggered airway inflammation causing chronic recur-
rent airflow obstruction. Long-term exposure to silica, asbestos, or
coal particles can cause chronic occupational lung disease called
pneumoconiosis.
The innate immune system is a key player in various infectious
and non-infectious disorders of the lung (7–9). It senses infec-
tions, sterile tissue damage, and probably any disturbance of host
cell and tissue integrity by so-called pattern-recognition recep-
tors (PRRs). PRRs comprise different protein families such as the
transmembrane Toll-like receptors (TLRs) and the intracellularly
located nucleotide-binding oligomerization domain (NOD)-like
receptors (NLRs) (10–12). PRRs recognize conserved microbial
molecules, referred to as pathogen-associated molecular patterns
(PAMPs) (13). However, recent evidence suggests that recogni-
tion of disturbed host cell integrity and danger signals might
also play a role in the immune responses to invading pathogens
(see below). In contrast to the original paradigm (13) it is now
well-accepted that PRRs also sense non-microbial ligands gener-
ated during sterile tissue damage, often called damage-associated
molecular patterns (DAMPs) (14, 15). Moreover, some PRRs can
additionally respond to large particles and therefore appear to be
key mediators in pneumoconiosis (16–18).
The NLR family comprises 22 members in humans and even
more in mice. Most NLRs share common structural character-
istics including a C-terminal leucine-rich repeat (LRR) domain,
often involved in ligand recognition, a central NOD, and a vari-
able N-terminal effector domain (10). Based on the type of effector
domains that is either a caspase recruitment domain (CARD), a
pyrin domain (PYD), or a baculoviral inhibitor of apoptosis pro-
tein repeat (BIR) domain, the NLR family can be further divides
into five subfamilies. The NLRA subfamily consist of only one
member, the transcription factor CIITA, of which at least one
splice variant expresses a CARD (Figure 1). CIITA is involved
in transcriptional activation of genes encoding major histocom-
patibility complex class II [for detailed discussion of this unique
NLR protein we refer to Ref. (19)]. The NLRB group of NLRs
expresses a BIR domain and consists of NAIP1–7 in mice and NAIP
in humans. The NLRC subfamily includes the CARD-containing
molecules NOD1, NOD2, and NLRC3–5, whereas the 14 known
NLRP proteins (NLRP1–14) express a PYD. NLRX1 is the only
member of the NLRX subgroup, and the only NLR protein that is
localized in mitochondria (10, 20). Whereas some NLR proteins
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FIGURE 1 | Summary of the main characteristics of the NLRs. h and m symbolized a characteristic specific to human or mouse. For more details, refer to the
main text.
function as bona fide PRRs, other family members act as adaptor
molecules or regulators of signal transduction.
In this review article we discuss the current knowledge about
NLR expression and function in the lung in different pulmonary
diseases. We have grouped the NLRs based on functional similar-
ities and summarize major pathways and common principles of
function.
NOD1 AND NOD2
NOD1 and NOD2 were the first NLR proteins to be discovered
(21–25). In the lung, NOD1 is expressed in various cell types
including lung epithelial cells, endothelial cells, human airway
smooth muscle cells, and different types of leukocytes (26–29).
NOD2 has been found in alveolar macrophages, neutrophils, and
bronchial epithelial cells (30–32). NOD1 responds to bacterial cell
wall peptidoglycan containing meso-diaminopimelic acid found
predominantly in Gram-negative bacteria (33, 34). NOD2 rec-
ognizes the muramyl-dipeptide (MDP) MurNAc-l-Ala-d-isoGln,
which is conserved in peptidoglycans of the majority of bacteria
(35, 36). Other peptidoglycan motifs can be recognized by NOD1
and NOD2, for details refer to review (37).
Ligand recognition by both receptors leads to signal transduc-
tion through Rip2 kinase with downstream activation of MAP
kinases and the transcription factor NF-κB, leading to activation
of genes encoding different cytokines, chemokines (e.g., IL-8),
and antimicrobial peptides. Both NOD signaling cascades are
regulated by small GTPases such as Rac1, however conflicting evi-
dence exists as to whether this regulation enhances or reduces
NOD-dependent NF-κB activation (38–40). A recent study sug-
gested that Rac1 is activated upstream of NOD1, and that NOD1
essentially senses GTPase activation rather than the peptidoglycan
fragments directly (41). NOD1 and NOD2 can recruit the GTPase
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ATG16L1 and subsequently stimulate autophagy, a highly con-
served bulk degradation system with antimicrobial activity against
intracellular pathogens (42).
Among the studied lung pathogens, NOD1 responds to
Chlamydophila pneumoniae, Legionella pneumophila, Klebsiella
pneumoniae, Haemophilus influenzae, and Pseudomonas aerug-
inosa (32, 40, 43–47), whereas NOD2 senses S. pneumoniae,
S. aureus, Escherichia coli, C. pneumoniae, and Mycobacterium
tuberculosis (30–32, 44, 48–50) (Figure 2). Accordingly, Rip2−/−
mice – and to a lesser extend also Nod1−/− and Nod2−/− mice –
display impaired chemokine production, neutrophil recruitment,
and reduced antibacterial defense in response to pulmonary C.
pneumoniae or L. pneumophila infection (32, 44). NOD2 is also
required for efficient antibacterial innate and adaptive immunity
in the chronic phase of pulmonary M. tuberculosis infection (51),
and polymorphisms in the human NOD2 gene have been asso-
ciated with resistance or susceptibility to tuberculosis (52). Of
note, mycobacteria express N-glycolylated MDP that has a stronger
NOD2-activating potential compared to the MDP (53). NOD2
controls inflammatory responses to S. aureus pneumonia (49),
and it is also required to clear pneumococcal colonization of the
upper respiratory tract by CCR2-dependently recruited mono-
cytes/macrophages. It was shown that professional phagocytes
produce CCL2 after LysM-mediated bacterial digestion and subse-
quent NOD2-dependent detection of S. pneumoniae-derived pep-
tidoglycan (48). Similarly, NOD1 controls neutrophil-dependent
clearance of nasopharyngeal colonization with encapsulated H.
influenzae in mice, whereas it is redundant for non-encapsulated
strains (46). NOD1 might critically regulate microbial competi-
tion in the upper respiratory tract as H. influenzae derived pepti-
doglycan fragments activate NOD1, which instructs neutrophils to
clear co-colonizing S. pneumoniae (54). Finally, one study impli-
cated NOD2 in antiviral immunity to RSV and influenza virus
infections (55).
Importantly, NOD proteins might also indirectly regulate
immune responses in the respiratory tract. An elegant study by
FIGURE 2 | Representation of NLRs involved in lung infections.
Various lung pathogens can be sensed by different NLR. These NLRs
either form inflammasomes to regulate IL-1 family cytokines and
pyroptotic cell death, stimulate production of NF-κB-dependent
inflammatory mediators, regulate autophagy, or control ROS
production.
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Weiser and colleagues showed than intestinal microbiota-derived
NOD1 ligands translocate into the circulation and the bone mar-
row, where it enhances protective neutrophil functions in the
periphery. This NOD1 induced neutrophil activation is required
for efficient clearance of S. pneumoniae or S. aureus from the
respiratory tract (56). NOD2 regulates the composition of the
intestinal microbiota in mice (57, 58) and one might speculate
about a similar function in shaping microbial communities in the
upper respiratory tract.
Finally, NOD1 and NOD2 have been implicated in granuloma-
tous and allergic lung diseases. For example, a genetic variation in
NOD1 was found to be associated with increased susceptibility to
sarcoidosis in a Japanese cohort (59), and NOD2 polymorphisms
were associated with severe pulmonary sarcoidosis in Caucasian
patients (60). NOD1 as well as NOD2 polymorphisms have been
associated with increased risk of developing allergy and allergic
asthma (61–64). Moreover, intranasal delivery of NOD2 ligands
was shown to inhibit airway tolerance to antigens by modu-
lating the Treg/Th2-cell balance (65). However, the function of
NOD1/2 in these diseases remains ill-defined as compared to their
well-established role in host defense.
NLRP PROTEINS
The NLRP subgroup of NLRs comprises 14 proteins of which
NLRP1, NLRP3, NLRP6, NLRP7, and NLRP12 form multipro-
tein complexes termed inflammasomes, consisting of one or two
NLR proteins, the adapter molecule ASC and pro-caspase-1 (20).
Inflammasomes serve as platforms for autocatalytic caspase-1
activation, which in turn critically regulates IL-1β and IL-18 pro-
duction by processing their zymogens proIL-1β and proIL-18,
and induce an inflammatory form of cell death called pyroptosis.
Inflammasome activation has also been implicated in the produc-
tion of eicosanoids (66). A number of NLRPs, such as NLRP6 and
NLRP12 exert inflammasome-independent functions, like nega-
tive regulation of innate immune signaling pathways (as discussed
below).
NLRP1
NLRP1 was the first NLR protein to be described as forming an
inflammasome (67). In humans, NLRP1 is abundantly expressed
in myeloid cells, lymphocytes, and respiratory epithelial cells (68).
A biochemical study showed that purified human NLRP1 can form
an active inflammasome with ASC and caspase-1 in presence of
MDP and ribonucleoside triphosphates (69). Nevertheless, it has
so far not been clearly confirmed that MDP can trigger NLRP1
inflammasome formation in human cells.
Mice possess three genes encoding NLRP1, which are present in
tandem on chromosome 11: NLRP1a, 1b, and 1c (70). Depending
on the genetic background, one, two, or three of these NLRP1s
can be expressed. Mouse NLRP1b senses lethal toxin (LT) of
Bacillus anthracis, leading to inflammasome activation (70, 71).
Using cells from wild-type and NLRPP1−/− mice, it was shown
that LT but not MDP could trigger the NLRP1 inflammasome
assembly (72). LT consists of two components: protective anti-
gen (PA) and lethal factor (LF). PA mediates cytosolic uptake of
LF, which has endopeptidase activity and cleaves several MAPK
kinases [reviewed in Ref. (73, 74)]. This way B. anthracis blocks
early immune responses by abrogating TLRs and NOD2 signal-
ing (75). The expression of NLRP1b and potentially NLRP1a
in macrophages, depending on the mouse background, leads to
resistance to LT (70, 72, 75, 76).
It is unclear if NLRP1 mediated LT resistance exists in human
cells, however it was mentioned in a recent review that the authors
had never observed LT resistance in macrophages isolated from
healthy human subjects (77). Studies in rats and mice, which also
present cell death induced by LT depending on NLRP1, showed
that LF-mediated cleavage of the N-terminal domain of NLRP1
leads to caspase-1 activation and IL-1β release (71, 78, 79). Inter-
estingly, a recent study indicated that a direct cleavage of murine
NLRP1b is sufficient to induce inflammasome activation in the
absence of LF,and proposed that NLRP1 might function as a sensor
of protease activity of multiple pathogens (79).
NLRP3
Expression of NLRP3 is strongly induced by inflammatory
cytokines and TLR agonists in myeloid cells (68, 80). Moreover,
low level expression has also been found in human bronchial
epithelial cells (81). Similar to the other inflammasomes, the
NLRP3 inflammasome mediates caspase-1-dependent process-
ing of proIL-1β as well as proIL-18 into their mature forms and
stimulates pyroptosis (20).
The NLRP3 inflammasome responds to a broad range of micro-
bial and non-microbial agents. Among lung pathogenic microor-
ganisms, K. pneumoniae, S. pneumoniae, S. aureus, C. pneumo-
niae, M. tuberculosis, L. pneumophila, influenza virus, human rhi-
novirus, RSV, and Aspergillus fumigatus have been shown to induce
NLRP3 activation (82–99). It is generally accepted that those
microbes or their molecules do not directly interact with NLRP3,
but instead microbe-induced disruption of host cell physiology
is sensed by NLRP3. The exact nature of the NLRP3 activating
signal remains somewhat elusive although production of reactive
oxygen species (ROS) (16, 100), mitochondrial dysfunction (101,
102), potassium efflux (103, 104), calcium mobilization (105),
have been implicated in NLRP3 inflammasome activation dur-
ing infection. Most pathogens stimulate ROS production in host
phagocytes, which might be involved in NLRP3 activation (85,
93). Furthermore, S. aureus, S. pneumoniae, M. tuberculosis, and
influenza virus disturb the cell membrane and/or the intracellu-
lar ionic concentrations by their pore-forming toxins, secretion
apparatus or ion channel proteins (82, 86–88, 96, 106). Other
pathogens might activate NLRP3 through an incompletely defined
mechanism upstream of NLRP3 that senses microbial RNA (107),
and Gram-negative bacteria stimulate a non-canonical caspase-11
inflammasome (108–111). Interestingly, NLRP3 inflammasome
activation by non-pathogenic bacteria that do not actively disrupt
host cell integrity is dependent on bacterial viability. Live but not
dead bacteria contain significant amounts of mRNA, the recog-
nition of which triggers NLRP3 inflammasome formation. This
response requires the adaptor protein TRIF, but it remains unclear
whether prokaryotic mRNA can directly activate NLRP3 or if it
is the result of a proximal signaling event. Detection of bacterial
mRNA is a key mechanism employed by the host immune sys-
tem to sense the presence of viable and thus infectious microbes
and thereby to scale the level of infectious threat (112, 113). These
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findings underscore the role of NLRP3 as a sensor of microbial
(and non-microbial) danger signals.
Several in vivo infection models have highlighted the central
role of NLRP3 in host defense. NLRP3 was required for efficient
antimicrobial responses against S. pneumoniae, K. pneumoniae,
and influenza A virus in vivo (84, 85, 87, 88). Interestingly, the
known susceptibility of aged mice toward influenza infection has
been attributed to a reduced expression of NLRP3, ASC, and
caspase-1 (114). It remains to be studied whether a similar mecha-
nism contributes to the elevated susceptibility of elder humans to
community-acquired pneumonia (115). Importantly, NLRP3 acti-
vation may also contribute to ALI, which was observed in a mouse
model of S. aureus pneumonia (96). The net effect of NLRP3
during pneumonia might thus dependent on the pathogen load,
the virulence of the pathogen and/or the expression of inflamma-
some components, as well as the susceptibility of the patient to
pulmonary damage.
Of note, NLRP3 (and even more pronounced the NLRP6;
see below) inflammasome activation in the gut shapes the
intestinal microbiota (116). The commensal microflora in turn
induces expression of NLRP3, proIL-1β, and proIL-18 in the lung
(117). This microflora driven host gene regulation is beneficial
since antibiotic depletion of the resident microbiota resulted in
markedly elevated susceptibility to influenza A virus infection in
mice (117).
Importantly, the NLRP3 inflammasome responds to a vast
range of sterile stimuli, particularly so-called DAMPs released
by dying cells including ATP, uric acid metabolites, biglycan
as well as hyaluronan (106, 118–121). Experimental studies in
mice suggest activation of NLRP3 by some of those DAMPs
might have important functions in the pathogenesis of ALI/ARDS,
COPD/emphysema, and lung fibrosis.
Efficient pulmonary gas exchange critically depends on the
integrity of the fragile lung barrier composed of the alveolar
epithelium and the endothelium of the pulmonary microvascu-
lature. ALI and ARDS can develop in the course of pneumonia,
sepsis, as a result of mechanical ventilation and hyperoxia, aspira-
tion of gastric content, or major trauma (6). ALI and ARDS are
characterized by a disrupted lung barrier, resulting in interstitial
and alveolar edema, impaired gas exchange, and in severe cases
organ failure and death. In addition, lung fibrosis may develop as
a long term consequence of ALI/ARDS. Bleomycin treatment as
a mouse model of acute inflammation and fibrosis results in uric
acid- and ATP-release by dying cells that stimulated NLRP3 acti-
vation and IL-1β production and IL-1R-mediated inflammation,
remodeling, and fibrosis (122–124). Bleomycin induced inflam-
mation and fibrosis can be rescued by treatment with IL-1R
antagonist (Anakinra) (123), allopurinol (impairs uric acid syn-
thesis), uricase (degrades uric acid) (122), and apyrase (degrades
ATP) (124). Moreover, it has been suggested that hyperoxia leads to
NLRP3 inflammasome activation, secretion of pro-inflammatory
cytokines, epithelial barrier dysfunction, and cell death (125, 126).
Mechanical ventilation was shown to enhance IL-18 levels in the
lung and serum, and inhibition of caspase-1 or IL-18 reduced
ventilation-induced lung injury (127). Human ARDS patients
express increased mRNA levels of inflammasome-related genes
and IL-18 protein in their peripheral blood (127).
NLRP3 inflammasomes might also contribute to pathogenesis
of chronic pulmonary disorders such as COPD and emphysema.
Concentrations of uric acid is increased in broncho-alveolar fluid
(BALF) of smokers and individuals with COPD as compared to
healthy controls (128). COPD patients also have reduced levels of
IL-1R antagonist (IL1RA) compared to controls (129). The mouse
model of elastase-induced emphysema depends on uric acid,
NLRP3,ASC,IL-1R,and MyD88 as critical mediators of inflamma-
tion, alveolar wall destruction, and fibrosis (130). Conflicting data
exist regarding the contribution of the NLRP3 pathway in tobacco
smoke-induced pulmonary inflammation. Whereas the study by
Doz et al. indicated that smoke-induced inflammation is mediated
by TLRs, the purinergic receptor P2X7, caspase-1, and IL-1R (131,
132), Pauwels et al. reported in another study that smoke-induced
pulmonary inflammation occurs independently of the NLRP3
inflammasome (133). Transgenic overexpression of mature IL-1β
in the lung epithelium of mice evokes a phenotype that closely
resembles COPD, including inflammation, emphysema, airway
fibrosis, and mucus cell metaplasia (134). Finally, H. influenzae
infection induces NLRP3 expression and activation in human lung
tissue, which might be a mechanism of infection-triggered COPD
exacerbations (135). These studies together indicate an important
role of caspase-1 and IL-1β in COPD and emphysema.
Conflicting evidence exists regarding the role of NLRP3
inflammasome-dependent IL-1β production in experimen-
tal asthma. Whereas ovalbumin-induced airway inflammation
requires NLRP3 and IL-1β, house dust mite allergens induce
pathology in an NLRP3-independent fashion (136, 137).
Pneumoconiosis is an occupational lung disease resulting from
long-term exposure to silica, asbestos, or coal particles. It is char-
acterized by pulmonary inflammation as well as fibrosis, which
may be driven by NLRP3 inflammasome activation. It has been
shown that engulfment of silica or asbestos crystals by resident
macrophages leads to NLRP3 inflammasome activation and IL-1β
production (16–18). It was suggested that crystal-induced inflam-
masome formation is a consequence of phagolysosomal disruption
and leakage of enzymes such as cathepsin B into the cytoplasm
(18). Nlrp3−/− and Asc−/− mice are protected from silica or
asbestos-induced granuloma formation and fibrosis (16, 17). In
contrast, mesothelioma development, a serious long term conse-
quence of asbestosis, appears to be independent of NLRP3 (138).
A recent case-control study in a Chinese population suggested
that a NLRP3 polymorphisms may confer increased risk for coal
workers’ pneumoconiosis (139).
Taken together, NLRP3 is a key sensor of disturbed cell and
tissue integrity during infectious and non-infectious pulmonary
disorders.
NLRP4
NLRP4 has been proposed to be involved in reproduction in mam-
mals (140–142). Nevertheless, NLRP4 expression in humans is
found in various organs including the lung (142–144). In vitro,
this NLR has the feature of a negative regulator of inflamma-
tory responses by lowering NF-κB activation and IFNβ production
(143, 144). Another particularity of NLRP4 is that its PYD is struc-
turally different compared to the one in other NLRs, leading to the
absence of interaction of NLRP4 with ASC (145). Besides, it has
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been described that NLRP4 negatively controls autophagy during
group A streptococcal infection by interacting with the autophagy
regulator Beclin-1 (146). However, in the absence of conditional
gene-targeted mice it is hard to predict a functional contribution
of NLRP4 to pathologies in the lung.
NLRP6
NLRP6 has been indicated to fulfill anti-inflammatory func-
tions by inhibiting NF-κB signaling downstream of, e.g., TLRs in
macrophages and mouse (147). Moreover, elegant studies by the
Flavell’s laboratory showed that NLRP6 can form an inflamma-
some in intestinal epithelial cells that appears to sense components
of the gut microflora and in turn regulates the composition of this
flora through IL-18 (116). Related or unrelated to these mecha-
nisms, NLRP6 has also been implicated in wound healing of the
intestinal mucosa (148). NLRP6 have so far been mainly described
in intestinal epithelial cells, neutrophils, and macrophages (116,
147) but our own unpublished data show expression of this pro-
tein also in activated murine alveolar epithelial cells (data not
shown). The function of NLRP6 in the lung has, however, not
been studied yet.
NLRP7
The NLRP7 gene is only present in humans and it is expressed in
peripheral blood mononuclear cells (PBMCs) upon LPS and IL-1β
stimulation (149). Gene silencing experiments in human mono-
cytes and macrophages recently indicated that NLRP7 responds
to bacterial lipopeptides and Mycoplasma as well as S. aureus
infections by forming an inflammasome (150). Its precise func-
tion during bacterial infections remains unknown, and no data is
available regarding its role in pulmonary physiology.
NLRP12
NLRP12 is expressed mainly in myeloid cells (151–153). Its expres-
sion is reduced by TLR stimulation and TNFα (151, 154) NLRP12
has been described as a negative regulator of classical and non-
classical NF-κB activation downstream of TLR or cytokine recep-
tors, by interacting with IKK and NIK (151, 155, 156). Further-
more, NLRP12 has been indicated to form an inflammasome,
however this has so far only been observed upon Yersinia pestis
infection (157). Finally, NLRP12 might play a role in adaptive
immunity by controlling migration of DCs to the draining lymph
nodes (153). NLRP12−/− mice did not respond differently to M.
tuberculosis and K. pneumoniae lung infections and allergic airway
inflammation wild-type mice in (158, 159), suggesting a functional
redundancy with other NLRs, or a minor contribution of NLRP12
to inflammatory processes in the lung.
NLRC4 AND NAIP PROTEINS
NAIP5 and NLRC4 are expressed in the cytosol of bone-marrow
and alveolar macrophages. A polymorphism in NAIP5 (also called
Bircle) has long been known to affect resistance of inbred mice
toward L. pneumophila (160, 161). Whereas most mice strains
are resistant against L. pneumophila infection due to a func-
tional NAIP5, A/J mice expressing a NAIP5 that differs in 14
amino acids or NAIP5−/− mice allow L. pneumophila replica-
tion (162–164). This NAIP5-mediated resistance against L. pneu-
mophila is dependent on detection of flagellin (162, 165), and on
pyroptosis of the infected macrophage as well as effects on the
trafficking of the Legionella-containing vacuole (166, 167). Sim-
ilarly, NLRC4 is well known for mediating caspase-1-dependent
responses to L. pneumophila and other flagellated bacteria (168–
171). NLRC4, however, also respond to bacteria that express a
type 3 secretion system (T3SS) including, for example, P. aerugi-
nosa (172–176). Of note, the Pseudomonas T3SS effector protein
ExoU can inhibit this inflammasome activation (176). One study
suggested that NLCR4 is partially involved in the production of
IL-1β and inflammasome-independent cytokines upon K. pneu-
moniae infection in vivo (177), even though K. pneumoniae does
neither express flagella nor T3SS.
It is now clear that murine NLRC4 forms together with either
NAIP5 (and possibly NAIP6) or NAIP2 two different inflamma-
somes that recognize flagellin or T3SS rod proteins, respectively
(178, 179). These inflammasomes appear to regulate IL-1β/IL-18
through ASC and pyroptosis independently of ASC (175,180,181).
The exact function of human NAIP is currently incompletely
understood. We and others suggested that hNAIP can detect and
restrict flagellated Legionella (182–184), whereas others indicated
recognition of bacterial T3SS needle proteins by hNAIP (178).
NLRC3 AND 5
NLRC3 is expressed in macrophages as well as lymphocytes and has
been suggested to function as a negative regulator of the early TLR
signaling (185). NLRC5 is highly expressed in mouse and human
lung tissue. Its expression can be further induced by IFNγ and LPS
in macrophages (186–189). NLRC5 protein has been described to
inhibit IL-1β, TNFα, and IL-6 productions in macrophages upon
viral infection. Its most prominent role is probably in adaptive
immunity by enhancing the transcription of MHC class I related
genes (186, 187, 189–197). In light of these data, NLRC5 involve-
ment in pulmonary infection such as influenza infection will be
an interesting area of study.
NLRX1
NLRX1 is ubiquitously expressed and located at the mitochondria
due to an N-terminal mitochondrial targeting sequence, although
the precise location (matrix or outer membrane) is still controver-
sial (198, 199). The C-terminal LRR domain has been shown to
bind to RNA but not to DNA by (200). Silencing of NLRX1 expres-
sion or knockout at the exons 4–5 in mice leads to exacerbated
immune responses in vivo upon TLR stimulation and influenza or
Sendai virus infections (201, 202). Knockout of the first four exons
or exon 3, however, had no influence on the immune response to
Sendai and influenza virus infections (203, 204). Instead, NLRX1
might function as an inducer of mitochondrial ROS production
(205). This is consistent with the finding of two different groups
that NLRX1 interacts with a protein of the mitochondrial res-
piratory chain (198, 203). Finally, NLRX1 has been indicated to
regulate autophagy (206). Further work is clearly needed to clarify
the function and exact mode of action of this unique NLR protein
in general and in the lung in particular.
CONCLUDING REMARKS
Nucleotide-binding oligomerization domain-like receptors pro-
teins are without doubt key players in the innate immune
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responses to infectious and sterile inflammatory diseases of the
lung, although many functions of several NLR family members,
particularly in the lung, are still unknown. Many NLRs respond
in functional cooperation with other innate sensors to invading
microbes, particles, and endogenous danger signals after tissue
damage. In similarity to possibly most immune receptors they
can exert beneficial or detrimental functions, depending on the
magnitude and the context of their activation. Increasing knowl-
edge on specific activators and inhibitors of these pathways might
help to manipulate them therapeutically in the not-so-distant
future.
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